Newsfeeds Archive - Page 480 of 19074

1 minute read

Oncocyte VitaGraft Kidney Study Results Published In The New England Journal Of Medicine

May 30, 4:50 PM

Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims

OCX

1 minute read

Quantum-Si Appoints Chuck Kummeth, To Serve As Independent Chairman Of The Board Of Directors, Effective May 27, 2024.

By Benzinga Newsdesk

May 30, 4:47 PM

Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the

QSI

3 minute read

T-Mobile US’s Options: A Look at What the Big Money is Thinking

By Benzinga Insights

May 30, 4:46 PM

Whales with a lot of money to spend have taken a noticeably bullish stance on T-Mobile US. Looking…

TMUS

3 minute read

A Closer Look at Occidental Petroleum’s Options Market Dynamics

By Benzinga Insights

May 30, 4:46 PM

Investors with a lot of money to spend have taken a bullish stance on Occidental Petroleum (NYSE:OXY). And…

OXY

2 minute read

Smart Money Is Betting Big In ORCL Options

By Benzinga Insights

May 30, 4:46 PM

Whales with a lot of money to spend have taken a noticeably bullish stance on Oracle. Looking at…

ORCL

1 minute read

Oncternal Completes Enrollment And Dosing Initiated For 5th Dose Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer

By Benzinga Newsdesk

May 30, 4:45 PM

Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for

ONCT

1 minute read

NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024

By Benzinga Newsdesk

May 30, 4:43 PM

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a

NXTC

2 minute read

Ulta Beauty Reports Better-Than-Expected Q1 Results, Lowers FY24 Guidance

By Erica Kollmann

May 30, 4:35 PM

Ulta Beauty reported its first-quarter financial results after the bell Thursday. Here's a look at the key figures from the report.

ULTA

1 minute read

Asana Sees Q2 EPS $(0.09)-$(0.08) Vs $(0.05) Est.; Revenue $177M-$178M Vs $177.2M Est.; FY25 EPS $(0.21)-$(0.19) Vs $(0.20) Est.; Revenue $719M-$724M Vs $722.06M Est.

By Benzinga Newsdesk

May 30, 4:32 PM

Financial OutlookFor the second quarter of fiscal 2025, Asana expects:Revenues of $177.0 million to $178.0 million, representing year over year growth of 9% to 10%.Non-GAAP operating loss of $23.0 million to $21.0

ASAN

2 minute read

Commodities

Regulatory Approvals For US Steel Deal; BHP-Anglo American Deal Falls Through; US GoldMining Sustainability Highlights And More: Thursday’s Top Mining Stories

By austin@walkonholdings.com

May 30, 4:31 PM

Regulatory Approvals For U.S. Steel Deal; BHP-Anglo American Deal Falls Through; U.S. GoldMining Sustainability Highlights And More: Thursday's Top Mining Stories

AAUKF